Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up
Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would…
















